Explain When Study Results Are Clinically Meaningful to Patients
It can be hard to decide whether STATISTICALLY significant findings are CLINICALLY significant.
Consider the new COMPASS trial in patients with stable CV disease. It's stirring up controversy...and is a good example.
It suggests that adding rivaroxaban (Xarelto) 2.5 mg BID to low-dose aspirin reduces the risk of a CV event versus aspirin alone...with a p-value less than 0.001.